Adhesion and Safety of Rotigexole Compared to Neupro
Status:
NOT_YET_RECRUITING
Trial end date:
2025-10-30
Target enrollment:
Participant gender:
Summary
A non-inferiority open-labelled crossover randomized controlled trial, of two arms, to investigate the adhesiveness and safety of Rotigexole 8 mg/24 hours transdermal patch, manufactured by Eva pharma, Egypt, compared to the innovator product, Neupro 8 mg/ 24 hours transdermal patch, manufactured by UCB Pharma S.A., Belgium, after 24 hours of application